| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
5,780,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.3302 - $0.3302 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Manufacturers - Major |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Phio Pharmaceuticals is developing therapeutics that use its INTASYL™ technology to target both tumor and immune cells by regulating genes to strengthen a patient's immune system while weakening tumor defense mechanisms. Co.'s INTASYL-based therapeutics are used to: strengthen immune cells, for example those administered as part of adoptive cell therapy (ACT), and directly modify cells in the tumor microenvironment to weaken a tumor's defense. Co.'s lead product candidate being developed by Co. in ACT is PH-762. Co.'s second product candidate in development for use in ACT is PH-894. Co.'s INTASYL compound PH-804 is also being developed for use in ACT.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
2,500 |
2,500 |
6,500 |
22,216 |
| Total Buy Value |
$2,275 |
$2,275 |
$14,195 |
$22,362 |
| Total People Bought |
1 |
1 |
2 |
2 |
| Total Buy Transactions |
1 |
1 |
4 |
12 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-25 |
2023-11-24 |
2023-05-26 |
2022-05-26 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Dispersyn Gerrit |
President & CEO |
• – – |
2020-08-19 |
4 |
B |
$2.50 |
$5,000 |
D/D |
2,000 |
16,377 |
2.74 |
- |
|
| Dispersyn Gerrit |
President & CEO |
• – – |
2020-03-01 |
4 |
D |
$2.93 |
$1,972 |
D/D |
(673) |
14,628 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2019-11-18 |
4 |
A |
$0.10 |
$23,750 |
D/D |
237,500 |
279,030 |
|
- |
|
| Bitterman Robert J |
Director |
– • – |
2019-11-18 |
4 |
A |
$0.10 |
$30,000 |
D/D |
300,000 |
320,440 |
|
- |
|
| Dispersyn Gerrit |
President & CEO |
• – – |
2019-11-18 |
4 |
A |
$0.10 |
$35,000 |
D/D |
350,000 |
827,817 |
|
- |
|
| Ferrara Robert L |
Director |
– • – |
2019-11-18 |
4 |
A |
$0.10 |
$12,750 |
D/D |
127,500 |
127,500 |
|
- |
|
| Cauwenbergh Geert |
Director |
– • – |
2019-11-18 |
4 |
A |
$0.10 |
$22,500 |
D/D |
225,000 |
704,841 |
|
- |
|
| Cauwenbergh Geert |
Director |
– • – |
2019-08-01 |
4 |
D |
$0.40 |
$706 |
D/D |
(1,751) |
479,841 |
|
- |
|
| Kontulis Caitlin |
Secretary & VP Finance & Admin |
• – – |
2019-08-01 |
4 |
D |
$0.40 |
$302 |
D/D |
(749) |
41,530 |
|
- |
|
| Dispersyn Gerrit |
President & CEO |
• – – |
2019-08-01 |
4 |
D |
$0.40 |
$498 |
D/D |
(1,236) |
477,817 |
|
- |
|
| Barrett John A |
Chief Development Officer |
• – – |
2019-04-22 |
4 |
A |
$0.00 |
$0 |
D/D |
222,991 |
222,991 |
|
- |
|
| Dispersyn Gerrit |
President & CEO |
• – – |
2019-03-01 |
4 |
A |
$0.00 |
$0 |
D/D |
407,703 |
479,053 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2019-02-28 |
4 |
A |
$0.38 |
$57,887 |
D/D |
152,415 |
481,592 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2019-02-15 |
4 |
A |
$0.36 |
$8,096 |
D/D |
22,279 |
329,177 |
|
- |
|
| Dorman H. Paul |
Director |
– • – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,375 |
|
- |
|
| Dispersyn Gerrit |
President & COO |
• – – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
55,000 |
71,350 |
|
- |
|
| Bitterman Robert J |
Director |
– • – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,440 |
|
- |
|
| Freeman Jonathan E |
Director |
– • – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
| Brownlie Keith L |
Director |
– • – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,000 |
|
- |
|
| Lockshin Curtis |
Director |
– • – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
10,000 |
20,130 |
|
- |
|
| Kontulis Caitlin |
Secretary & Sr. Dir. Finance |
• – – |
2019-02-13 |
4 |
A |
$0.00 |
$0 |
D/D |
27,000 |
40,214 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2019-02-01 |
4 |
A |
$0.38 |
$8,096 |
D/D |
21,470 |
306,898 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2019-01-18 |
4 |
A |
$0.34 |
$8,096 |
D/D |
23,729 |
285,428 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2019-01-04 |
4 |
A |
$0.35 |
$8,096 |
D/D |
23,139 |
261,699 |
|
- |
|
| Cauwenbergh Geert |
Chief Executive Officer |
• • – |
2018-12-21 |
4 |
A |
$0.30 |
$8,096 |
D/D |
27,445 |
238,560 |
|
- |
|
134 Records found
|
|
Page 3 of 6 |
|
|
